UY32546A - Composiciones y metodos para tratar cancer - Google Patents
Composiciones y metodos para tratar cancerInfo
- Publication number
- UY32546A UY32546A UY0001032546A UY32546A UY32546A UY 32546 A UY32546 A UY 32546A UY 0001032546 A UY0001032546 A UY 0001032546A UY 32546 A UY32546 A UY 32546A UY 32546 A UY32546 A UY 32546A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- compositions
- treat cancer
- decitabine
- inactivation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 abstract 2
- 229960003603 decitabine Drugs 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009615 deamination Effects 0.000 abstract 1
- 238000006481 deamination reaction Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proveen en la presente métodos de tratamiento de cáncer que comprenden la administración de decitabina en combinación con compuestos que inhiben la enzima de desaminación responsable de la inactivación de la decitabina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16711909P | 2009-04-06 | 2009-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32546A true UY32546A (es) | 2010-10-29 |
Family
ID=42357480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032546A UY32546A (es) | 2009-04-06 | 2010-04-06 | Composiciones y metodos para tratar cancer |
Country Status (11)
Country | Link |
---|---|
US (1) | US8329666B2 (es) |
EP (1) | EP2416780B1 (es) |
JP (1) | JP5730854B2 (es) |
AR (1) | AR076263A1 (es) |
AU (1) | AU2010234641B2 (es) |
CA (1) | CA2757744C (es) |
ES (1) | ES2628580T3 (es) |
JO (1) | JO3262B1 (es) |
TW (1) | TWI503121B (es) |
UY (1) | UY32546A (es) |
WO (1) | WO2010118010A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
ES2628609T3 (es) * | 2009-04-06 | 2017-08-03 | Otsuka Pharmaceutical Co., Ltd. | Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer |
US8324180B2 (en) * | 2009-04-06 | 2012-12-04 | Eisai Inc. | Compositions and methods for treating cancer |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
JP7194021B2 (ja) | 2015-12-03 | 2022-12-21 | エピデスティニー,インコーポレイテッド | デシタビン、5アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用 |
ES2905478T3 (es) | 2016-12-28 | 2022-04-08 | Transgene Sa | Virus oncolíticos y moléculas terapéuticas |
US11224610B2 (en) | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
WO2020201967A1 (en) | 2019-03-29 | 2020-10-08 | Novocure Gmbh | Methods for restoring sensitivity to ttfields in ttfields-resistant cancer cells with ptger3 inhibitors |
AU2022370354A1 (en) | 2021-10-19 | 2024-05-30 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017606A (en) * | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
US4275057A (en) * | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
EP0160079B1 (en) | 1983-10-26 | 1990-01-31 | GREER, Sheldon B. | Method and materials for sensitizing neoplastic tissue to radiation |
IL77133A (en) * | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
FR2682112B1 (fr) * | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
US5371210A (en) * | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5426183A (en) * | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5606048A (en) * | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5821357A (en) * | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5594124A (en) * | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
DE69403588T2 (de) * | 1993-02-23 | 1998-01-22 | Hope City | 4-ethoxy-5-fluor-2'-deoxyuridine |
WO1994026761A1 (en) | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
US5521294A (en) * | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
US6001994A (en) * | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
US5760208A (en) * | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
US6933287B1 (en) * | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
DE60030842T2 (de) | 1999-03-01 | 2007-05-10 | Halogenetics Inc., Aventura | VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN |
US6462191B1 (en) * | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
EP1348712B1 (en) | 2000-11-29 | 2011-05-04 | Mitsui Chemicals, Inc. | Processes and intermediates in the synthesis of L-thymidine |
EP1353693B1 (en) * | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
WO2002094844A2 (en) | 2001-05-18 | 2002-11-28 | Rakesh Kumar | Antiviral nucleosides |
WO2004028454A2 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
US8158770B2 (en) * | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
EP1812457A1 (en) | 2004-07-30 | 2007-08-01 | Pharmaessentia Corp. | STEREOSELECTIVE SYNTHESIS OF ß-NUCLEOSIDES |
JP2007522151A (ja) | 2004-12-08 | 2007-08-09 | シコール インコーポレイティド | ジフルオロヌクレオシド及びその調製方法 |
WO2008085611A2 (en) | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
US8324180B2 (en) * | 2009-04-06 | 2012-12-04 | Eisai Inc. | Compositions and methods for treating cancer |
ES2628609T3 (es) * | 2009-04-06 | 2017-08-03 | Otsuka Pharmaceutical Co., Ltd. | Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer |
-
2010
- 2010-04-06 CA CA2757744A patent/CA2757744C/en active Active
- 2010-04-06 ES ES10713755.6T patent/ES2628580T3/es active Active
- 2010-04-06 AR ARP100101143A patent/AR076263A1/es not_active Application Discontinuation
- 2010-04-06 EP EP10713755.6A patent/EP2416780B1/en active Active
- 2010-04-06 WO PCT/US2010/030078 patent/WO2010118010A1/en active Application Filing
- 2010-04-06 US US12/755,122 patent/US8329666B2/en active Active
- 2010-04-06 TW TW099110582A patent/TWI503121B/zh active
- 2010-04-06 AU AU2010234641A patent/AU2010234641B2/en active Active
- 2010-04-06 UY UY0001032546A patent/UY32546A/es active IP Right Grant
- 2010-04-06 JP JP2012504773A patent/JP5730854B2/ja active Active
- 2010-04-06 JO JOP/2010/0108A patent/JO3262B1/ar active
Also Published As
Publication number | Publication date |
---|---|
US20100279967A1 (en) | 2010-11-04 |
WO2010118010A1 (en) | 2010-10-14 |
ES2628580T3 (es) | 2017-08-03 |
JP5730854B2 (ja) | 2015-06-10 |
AR076263A1 (es) | 2011-06-01 |
EP2416780A1 (en) | 2012-02-15 |
CA2757744C (en) | 2018-02-13 |
TW201102072A (en) | 2011-01-16 |
JP2012522841A (ja) | 2012-09-27 |
US8329666B2 (en) | 2012-12-11 |
EP2416780B1 (en) | 2017-03-08 |
AU2010234641A1 (en) | 2011-11-10 |
AU2010234641B2 (en) | 2016-04-21 |
JO3262B1 (ar) | 2018-09-16 |
TWI503121B (zh) | 2015-10-11 |
CA2757744A1 (en) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32546A (es) | Composiciones y metodos para tratar cancer | |
NI201200090A (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
MY191825A (en) | Therapeutic compounds and compositions | |
CO6321188A2 (es) | Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp | |
ECSP10010697A (es) | Inhibidores de dpp-iv para uso en el tratamiento de nafld | |
MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
BR112015011830A2 (pt) | compostos e seus métodos de utilização | |
NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
CO6430487A2 (es) | Anticuerpos anti-her | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
GT200900146A (es) | Inhibidores de la actividad de la akt | |
DK2252322T3 (da) | Vaccinesammensætninger | |
PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
BR112012022243A2 (pt) | terapias inibidoras de autografia baseadas em tioxantona para tratar câncer | |
DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
IN2014DN08385A (es) | ||
CR20110022A (es) | Nuevas posibilidades de lucha contra la giardiasis | |
DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
110 | Patent granted |
Effective date: 20210907 |